Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
5.65
+0.33 (6.20%)
Sep 14, 2026, 4:00 PM EDT - Market closed

Aclaris Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.18. The average 1-year stock price forecast is 80.18% higher than the current stock price, while the lowest is $4.00 (-29.20%) and the highest is $16 (+183.19%).

Price Target: $10.18 (+80.18%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$10.18$10$16
Change-29.20%+80.18%+76.99%+183.19%

Analyst Ratings

The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy678999
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total8910111111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Initiates
$10
BuyInitiates$10+76.99%Sep 1, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$11
BuyMaintains$11+94.69%Aug 31, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$16
BuyReiterates$16+183.19%Aug 10, 2026
LifeSci Capital
LifeSci Capital
Buy
Maintains
$13
BuyMaintains$13+130.09%Aug 6, 2026
Craig-Hallum
Craig-Hallum
Buy
Maintains
$10
BuyMaintains$10+76.99%Aug 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.34M
from 7.83M
Decreased by -19.01%
Revenue Next Year
5.34M
from 6.34M
Decreased by -15.78%
EPS This Year
-0.64
from -0.53
EPS Next Year
-0.79
from -0.64
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
6.76M29.75M31.25M18.72M7.83M6.34M
Revenue Growth
4.30%340.05%5.03%-40.09%-58.19%-19.01%
Operating Income
-65.38M-85.15M-114.51M-52.53M-74.08M-98.92M
Net Income
-90.87M-86.91M-88.48M-132.07M-64.92M-90.33M
EPS
-----0.53-0.64
Free Cash Flow
-28.51M-39.31M-37.97M-59.12M-30.63M-90.50M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High7.9M
Avg6.3M
Low3.6M

Revenue Growth

Revenue Growth202620272028
High
0.6%
Avg
-19.0%
Low
-54.0%

EPS Forecast

EPS202620272028
High-0.54
Avg-0.64
Low-0.74

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-